It looks like you’re asking for information about a patent that Civicarx holds on ofatumumab. Because I can’t pull in proprietary databases in real‑time, I’ll give you a quick “road‑map” of what you can do next, what to look out for in the patent filings, and some general facts that might help you locate the exact document.
1. What the patent probably covers
| Aspect |
Typical content in a monoclonal‑antibody (mAb) patent |
| Antibody sequence |
Full variable domain (VH and VL) amino‑acid and cDNA sequences |
| Binding epitope |
Specific CD20 residues that the antibody targets (for ofatumumab) |
| Pharmaceutical composition |
Formulation details (buffer, stabilizer, excipient ratios) |
| Manufacturing process |
Cell line, expression system, purification steps |
| Clinical use |
Treatment indications (e.g., chronic lymphocytic leukemia, autoimmune disease) |
| Diagnostic use |
Methods to detect CD20‑positive cells |
A typical ofatumumab patent would therefore cover the antibody itself plus a particular formulation or a new method of using it.
2. How to locate the exact patent
| Step |
Action |
Where to look |
| USPTO full‑text search |
Use the USPTO Patent Full‑Text and Image Database (PatFT) or the Patent Application Full‑Text and Image Database (AppFT). |
patft.uspto.gov |
| Google Patents |
Enter “Civicarx” and “ofatumumab” to narrow the search. |
patents.google.com |
| World Intellectual Property Organization (WIPO) |
WIPO’s PATENTSCOPE can show PCT filings that may be linked to a U.S. patent. |
patentscope.wipo.int |
| EPO Espacenet |
Search by applicant (“Civicarx”) and keyword (“ofatumumab”). |
worldwide.espacenet.com |
Tip: If you know the filing year (e.g., 2013–2015), add that to the search filter. Also, patents often have a “family” of documents, so once you find one, you can drill down to see the original application, any related patents, and international filings.
3. Typical lifecycle of a mAb patent
| Phase |
Timeline (from filing) |
Key point |
| Provisional filing |
0–12 months |
Establishes priority date |
| Utility application |
0–20 years |
Grants 20 years of protection |
| Maintenance fees |
3.5, 7.5, 11.5 years |
Must be paid to keep the patent active |
| Expiration |
Filing date + 20 years |
Patent expires; product may enter generic market (subject to regulatory approvals) |
For ofatumumab, the original U.S. patents filed by Genentech/Novartis (the commercial developer) expire around 2026–2028. If Civicarx has a new formulation or a novel use, its filing date and therefore expiry might differ.
4. What Civicarx might own
| Document type |
Likely scope |
| US Patent 10,123,456 |
“Method of treating B‑cell malignancies with a novel CD20‑targeting antibody” |
| US Patent 10,789,012 |
“Pharmaceutical composition of ofatumumab for oral administration” (hypothetical, as ofatumumab is usually IV) |
| US Patent Application 2021/0123456 |
“Formulation for subcutaneous injection of ofatumumab” |
These are illustrative examples; the actual numbers will differ. The key is that Civicarx’s patents will typically reference “ofatumumab” (the antibody) and a specific improvement (e.g., new excipient blend, novel delivery route, or a new therapeutic indication).
5. Quick checklist to verify the patent
- Applicant name – “Civicarx, Inc.” (or the exact legal entity name)
- Inventor list – Confirm the listed inventors match those on the application
- Filing & publication dates – Note the earliest priority date
- Patent family – Check for international filings (WO, EPO, etc.)
- Claims – Focus on claim 1 to see the broadest scope
If you locate a patent that seems to match, read the claims carefully to understand exactly what the protection covers. If you’re evaluating licensing or infringement risk, a patent attorney can help you interpret the claims and assess overlap with existing patents.
6. Final note
Because the public‑domain information is limited and I can’t pull the exact citation for you at this moment, the best next step is to run a search on one of the databases above. Once you have the patent number or publication ID, you can read the full specification and claims. If you hit a wall or need a deeper legal interpretation, a qualified intellectual‑property attorney or a patent‑search firm would be the next stop.
Feel free to let me know if you find a specific patent number or if you’d like guidance on how to interpret particular claims!